Recombinant anti-CD52 humanized monoclonal antibody (Hisun Pharm)

重组抗CD52人源化单抗（海正药业）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant anti-CD52 humanized monoclonal antibody (Hisun Pharm)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCAMPATH-1 antigen inhibitors
TargetsCAMPATH-1 antigen
Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (IND)
Highest Status in ChinaDiscontinued
Originator CompaniesZhejiang Hisun Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesZhejiang Hisun Pharmaceutical Co LtdHisun Pharmaceutical (Hangzhou) Co Ltd
Active IndicationsN/A
Inactive IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A